Expression of parathyroid hormone related peptide in human pituitary tumours

M Ito, H Enomoto, T Usa, M C Villadolid, A Ohtsuru, H Namba, I Sekine, S Yamashita

Abstract
The presence of parathyroid hormone related peptide (PTHrP) was studied in 20 patients with pituitary adenomas and one patient with pituitary adenocarcinoma. PTHrP expression was shown in almost all of the pituitary adenomas (95%) and in 100% (n = 7) growth hormone producing pituitary adenomas. A metastatic lesion from a pituitary growth hormone producing adenocarcinoma revealed strongly expressed PTHrP. It was weakly detected in normal pituitary cells in all of the specimens (n = 10). There was no significant correlation, however, between PTHrP expression and the clinical or pathological features of growth hormone producing tumours. Apart from an important role in the physiological function of the pituitary gland, PTHrP may be closely related to somatotroph tumorigenicity.

Various growth factors occur in the human pituitary gland.1 These growth factors may be involved in the gland’s endocrine function regardless of whether they are actually produced by pituitary cells. Parathyroid hormone related peptide (PTHrP) was originally isolated from human tumour cells derived from patients with hypercalcaemia of malignancy,2 but the PTHrP gene is widely expressed in normal and neoplastic tissues and functions in a paracrine and an autocrine manner.3 Recently our preliminary data have demonstrated the presence of PTHrP mRNA in rat pituitary glands and in rat GH1 pituitary tumour cells. We therefore extended our study to human pituitary tissues to investigate the presence of PTHrP and analyse the association between pituitary gland cell types and positive PTHrP immunostaining.

Methods
We reviewed 10 normal pituitary glands and 20 pituitary adenomas obtained from surgical specimens or necropsy cases in Nagasaki University Hospital. The formalin fixed, paraffin wax embedded tissues were sectioned to 4 μm, dewaxed in xylene, and rehydrated in phosphate buffered saline. Dewaxed sections were preincubated with normal bovine serum to prevent non-specific binding, and then incubated with an optimal dilution (5 μg/ml) of the primary antibody of human PTHrP (Oncogene Science, Uniondale, New York, USA) overnight at 4°C. The slides were sequentially incubated with alkaline phosphatase conjugated goat anti-mouse immunoglobulin antibodies. The alkaline phosphatase reaction was demonstrated using a BCIP/NBT (BRL, Gaithersburg, Maryland). In all cases, Copenhagen immunohistochemical staining of growth hormone, prolactin, adrenocorticotropic hormone, thyroid stimulating and follicular stimulating hormone (Dakopatts (ABC)) was performed in serial sections using the avidin-biotin-peroxidase complex method with diaminobenzidine as the chromogenic substrate (Vectorstain Elite kits, Burlington, California), after exposure to a 0.3% solution of hydrogen peroxide in absolute methanol to block endogenous peroxidase. Cultured cells producing PTHrP (human squamous cell carcinoma cell line) served as internal positive controls in immunostaining for PTHrP. Negative controls were prepared by replacing the primary antibody with non-immune serum.

Results
PTHRP expression was occasionally seen in the anterior lobe of pituitary glands in all normal cases (n = 10). Among the variable endocrine cells, the immunoreactivity to PTHrP was relatively stronger in the cells secreting growth hormone by serial immunodetection (figs 1A and B). We found PTHrP immunoreactivity in all human pituitary tumours producing growth hormone. A metastatic lesion in the spinal cord from a pituitary adenocarcinoma strongly expressed PTHrP, suggesting growth hormone producing cells confirmed by both anti-growth hormone and anti-PTHrP antibody, respectively (figs 1C, D). Most pituitary adenomas stained for PTHrP, but the degree of positivity was different for each cell type. Primary and secondary cell adenomas were densely positive for PTHrP. Immunohistochemical staining results are summarised in the table. In prolactin producing adenomas and null cell adenomas, a weakly positive immunoreaction was usually observed. Somatotroph characteristics may feature in PTHrP positivity in prolactin cell adenomas. There was no significant correlation between PTHrP expression and clinical features, such as patient age or sex, or morphological features, such as tumour size.

Discussion
That PTHrP is present in normal human pituitary glands has been proved in this study,
PTHrP in human pituitary tumours

suggesting the co-localisation of growth hormone and PTHrP in the same mammotroph cell. This was supported by evidence of strong positivity of PTHrP in growth hormone producing pituitary tumours. There was only one case of invasive growth hormone producing adenocarcinoma, and the strongest positivity of PTHrP staining in this metastatic tumour suggests that a worsening prognosis and metastatic activity of somatotroph tumours are closely related to the induction of PTHrP gene by a mechanism similar to that of other PTHrP producing tumours. Northern blot analysis in human growth hormone producing pituitary tumours also confirmed the presence of multiple forms of PTHrP mRNA species (unpublished data). Furthermore, the human pituitary, especially the somatotroph cell, is known to secrete PTHrP in the local circulation to regulate pituitary function physiologically. Parathyroid hormone itself is a well known growth factor for pituitary tumour cell growth in rats, suggesting that PTHrP functions in the pituitary through a common parathyroid hormone PTHrP receptor. The presence of PTHrP mRNA in rat pituitary GH₃ tumour cells has already been shown. The paracrine/autocine role of PTHrP in normal pituitary function, however, remains to be evaluated. At present there is no single accurate predictor which can identify acromegalic patients with pituitary growth hormone producing tumours at risk of developing malignant changes and metastatic spread. In general, acromegalic patients are not hypercalcaemic, but the measurement of PTHrP in cerebrospinal fluid might help to evaluate the grade of malignancy of these tumours.

<table>
<thead>
<tr>
<th>Cell type and PTHrP immunoreactivity (No.% in human pituitary adenomas)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PTHR expression</strong></td>
</tr>
<tr>
<td><strong>Cell type</strong></td>
</tr>
<tr>
<td>Growth hormone cell adenoma</td>
</tr>
<tr>
<td>Prolactin cell adenoma</td>
</tr>
<tr>
<td>Null cell adenoma</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

Expression of parathyroid hormone related peptide in human pituitary tumours.

M Ito, H Enomoto, T Usa, M C Villadolid, A Ohtsuru, H Namba, I Sekine and S Yamashita

doi: 10.1136/jcp.46.7.682